Bioavailability of BI 1356 BS and Metformin After Co-administration Compared to the Bioavailability of BI 1356 BS Alone and Metformin Alone in Healthy Male Volunteers
- Registration Number
- NCT02183506
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
Investigate the bioavailability of BI 1356 BS and of metformin after concomitant multiple oral administration of 10 mg BI 1356 BS tablets and 3 x 850 mg metformin in comparison to BI 1356 BS and metformin given alone
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Male
- Target Recruitment
- 16
-
Healthy males according to the following criteria, based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead electrocardiogram (ECG), clinical laboratory tests
- No finding deviating from normal and of clinical relevance
- No evidence of a clinically relevant concomitant disease
-
Age ≥ 21 and Age ≤ 50 years
-
BMI (Body Mass Index) ≥ 18.5 and ≤ 29.9 kg/m2
-
Ability to give signed and dated written informed consent prior to admission to the study in accordance with good clinical practice (GCP) and the local legislation
- Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- Surgery of the gastrointestinal tract (except appendectomy)
- Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- History of relevant orthostatic hypotension, fainting spells or blackouts
- Chronic or relevant acute infections
- History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial by the investigator
- Intake of drugs with a long half-life (>24 hours) within one month or less than 10 half-lives of the respective drug prior to administration or during the conduct of this trial (review with clinical monitor if there is a question)
- Use of drugs which might reasonably influence the results of the trial (based on knowledge at the time of protocol preparation) within 10 days prior to administration or during the conduct of this trial
- Participation in another trial with an investigational drug within two months prior to administration or during the conduct of this trial
- Smoker (more than 10 cigarettes or 3 cigars or 3 pipes per day)
- Inability to refrain from smoking during the conduct of this trial
- Alcohol abuse (more than 60 g/day)
- Drug abuse
- Blood donation (more than 100 mL within four weeks prior to administration or during the conduct of this trial)
- Excessive physical activities (within one week prior to administration or during the conduct of this trial)
- Any laboratory value outside the normal reference range that is of clinical relevance
- Inability to comply with the dietary regimen of the study center
- No adequate contraception (condom use plus another form of contraception e.g., spermicide, oral contraceptive taken by female partner, sterilization) during the whole study period from the time of the first intake of study drug until one month after the last intake of drug
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description Metformin Metformin - BI 1356 BS and metformin Metformin Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9) BI 1356 BS and metformin BI 1356 BS Daily administration of BI 1356 BS alone (day 1 to day 6) followed by the combined treatment of BI 1356 BS with metformin (day 7 to day 9)
- Primary Outcome Measures
Name Time Method Area under the concentration-time curve (AUC) of the analytes in plasma at different time points up to 240 hours after start of treatment Maximum concentration (Cmax) of the analytes in plasma at different time points up to 240 hours after start of treatment
- Secondary Outcome Measures
Name Time Method Terminal rate constant of the analytes in plasma at steady state (λz,ss ) up to 240 hours after start of treatment Time from last dosing to maximum concentration of the analytes in plasma at steady state (tmax,ss) up to 240 hours after start of treatment Minimum concentration of the analytes in plasma at steady state (Cmin,ss) over a uniform dosing interval τ up to 240 hours after start of treatment Terminal half-life of the analytes in plasma at steady state (t1/2,ss ) up to 240 hours after start of treatment Mean residence time of the analytes in the body at steady state after oral administration (MRTpo,ss) up to 240 hours after start of treatment Apparent clearance of the analytes in the plasma at steady state (CL/F,ss) following extravascular multiple dose administration up to 240 hours after start of treatment Apparent volume of distribution during the terminal phase λz at steady state (Vz/F,ss) following extravascular administration up to 240 hours after start of treatment Measurements of dipeptidylpeptidase 4 (DPP-IV) activity up to 240 hours after start of treatment Number of patients with adverse events up to 60 days Number of patients with clinically abnormal changes in laboratory values Baseline, up to 14 days after last drug administration Number of patients with clinically relevant changes in vital signs Baseline, up to 14 days after last drug administration feτ,ss (fraction of the dose excreted unchanged in urine at steady state) 0-4 h, 4-8 h, 8-12 h and 12-24 hours after drug administration on days 3, 6, 9 CLR,ss (renal clearance of the analyte in plasma at steady state) 0-4 h, 4-8 h, 8-12 h and 12-24 hours after drug administration on days 3, 6, 9